The case for & against
Bull & Bear analysis
Bearish
AbCellera Biologics, Inc. (NASDAQ: ABCL) is a clinical-stage biotechnology company focused on the discovery and development of monoclonal antibodies for therapeutic applications, primarily targeting unmet medical needs in women’s health and oncology. Positioned within the biopharmaceutical sector, AbCellera leverages its proprietary technology to advance its innovative therapeutic pipeline, making it a notable player in the growing field of antibody development.
Bull says
- ↑Phase II ABCL635 trial readout expected in Q3 2026 targeting a $6 B market
- ↑Cash and equivalents of ~$530 M covers R&D and operations for next three years
- ↑Median analyst target implies 43% upside and a Strong Buy consensus
- ↑Revenue doubled to $8 M in Q1 2026 from $4 M a year ago
- ↑Favorable momentum signals and rising technical trend support share strength
- ↑High liquidity and modest dividend yield provide stability
Bear says
- ↓Q1 2026 net loss of $43 M with $47 M in R&D expenses drives significant cash burn
- ↓Profitability remains weak with negative earnings yield and leverage risk elevated
- ↓Short interest up 8.1% reflects diminishing investor confidence
- ↓Any Phase II setback could delay approvals and impair valuation
- ↓Dominant hormone therapies and emerging biologics intensify competitive pressure
- ↓High volatility may exacerbate share swings and deter risk‐averse investors
Investment themes with ABCL
Recent IPOs↓ -0.74%
Companies that recently went public
SNOW · PLTR · PTON
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-11-2026bullish
Transcript signals
Bull points
- the unblinded interim data from the single ascending dose cohort demonstrated that ABCL635 has a favorable tolerability profile, a PK profile that supports monthly subcutaneous dosing, and strong and sustained target engagement that meets or exceeds levels previously published for the approved small molecule, Fezolinatant.
- With these data, we moved quickly to initiate Phase II trials in January of this year. We selected a 600-milligram subcutaneous dose administered once because we believe it best approximates exposures of 300 milligrams at steady-state dosing and could be a feasible loading dose to initiate therapy and potentially maximize early effects on VMS.
- we are currently on track to release top line efficacy and safety data in Q3 of this year.
Bear points
- We expect this to generally trend lower as we focus on our internal pipeline.
- we are reporting a net loss of roughly $43 million for the first quarter of 2026
Read full transcript analysis ›